Complete response in myeloma: a Trojan horse?

被引：8

作者：

Barlogie, Bart ^{[1
]}

Tricot, Guido ^{[1
]}

机构：

[1] Univ Arkansas Med Sci, Little Rock, AR 72205 USA

来源：

BLOOD | 2006年 / 108卷 / 07期

关键词：

D O I：

10.1182/blood-2006-07-034538

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2134 / 2134

页数：1

共 10 条

[1] Single versus double autologous stem-cell transplantation for multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Facon, T ;

Guilhot, F ;

Doyen, C ;

Fuzibet, JG ;

Monconduit, M ;

Hulin, C ;

Caillot, D ;

Bouabdallah, R ;

Voillat, L ;

Sotto, JJ ;

Grosbois, B ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26) :2495-2502

[2]

BARLOGIC B, IN PRESS BR J HAEMAT

[3] Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies [J].

Barlogie, B ;

Tricot, G ;

Rasmussen, E ;

Anaissie, E ;

van Rhee, F ;

Zangari, M ;

Fassas, A ;

Hollmig, K ;

Pineda-Roman, M ;

Shaughnessy, J ;

Epstein, J ;

Crowley, J .

BLOOD, 2006, 107 (07) :2633-2638

[4] Thalidomide and hematopoietic-cell transplantation for multiple myeloma [J].

Barlogie, B ;

Tricot, G ;

Anaissie, E ;

Shaughnessy, J ;

Rasmussen, E ;

van Rhee, F ;

Fassas, A ;

Zangari, M ;

Hollmig, K ;

Pineda-Roman, M ;

Lee, C ;

Talamo, G ;

Thertulien, R ;

Kiwan, E ;

Krishna, S ;

Fox, M ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1021-1030

[5]

Facon T, 2006, J CLIN ONCOL, V24, p1S

[6]

Fassas A, 2005, BLOOD, V106, p342A

[7] Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial [J].

Palumbo, A ;

Bringhen, S ;

Coravito, T ;

Merla, E ;

Capporella, V ;

Callea, V ;

Cangialosi, C ;

Grasso, M ;

Rossini, F ;

Galli, M ;

Catalano, L ;

Zamagni, E ;

Petrucci, MT ;

De Stefano, V ;

Ceccarelli, M ;

Ambrosini, MT ;

Avonto, I ;

Falco, P ;

Ciccone, G ;

Liberati, AM ;

Musto, P ;

Boccadoro, M .

LANCET, 2006, 367 (9513) :825-831

[8] A phase 2 study of bortezomib in relapsed, refractory myeloma [J].

Richardson, PG ;

Barlogie, B ;

Berenson, J ;

Singhal, S ;

Jagannath, S ;

Irwin, D ;

Rajkumar, SV ;

Srkalovic, G ;

Alsina, M ;

Alexanian, R ;

Siegel, D ;

Orlowski, RZ ;

Kuter, D ;

Limentani, SA ;

Lee, S ;

Hideshima, T ;

Esseltine, DL ;

Kauffman, M ;

Adams, J ;

Schenkein, DP ;

Anderson, KC .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (26) :2609-2617

[9] Antitumor activity of thalidomide in refractory multiple myeloma. [J].

Singhal, S ;

Mehta, J ;

Desikan, R ;

Ayers, D ;

Roberson, P ;

Eddlemon, P ;

Munshi, N ;

Anaissie, E ;

Wilson, C ;

Dhodapkar, M ;

Zeldis, J ;

Barlogie, B ;

Siegel, D ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21) :1565-1571

[10] MRI-detectable focal lesions (FL) in multiple myeloma (MM) at relapse frequently involve novel sites not involved at diagnosis. [J].

Walker, R ;

Jones-Jackson, L ;

Rasmussen, E ;

Miceli, M ;

Anaissie, E ;

Epstein, J ;

Tricot, G ;

Shaughnessy, J ;

Barlogie, B .

BLOOD, 2004, 104 (11) :364B-365B

← 1 →